These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24761803)

  • 21. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
    Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
    Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone sensitivity of primary breast carcinoma.
    Filipovic S; Kocic B; Petrovic B; Milovanovic L; Poultsidi AA
    J BUON; 2010; 15(2):255-62. PubMed ID: 20658718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal receptor determination of 1,052 Chinese breast cancers.
    Chow LW; Ho P
    J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative image analysis of estrogen and progesterone receptors as a prognostic tool for selecting breast cancer patients for therapy.
    Castagnetta LA; Traina A; Liquori M; Marasà L; Amodio R; Di Falco M; Miele M; Rausa L; Carruba G
    Anal Quant Cytol Histol; 1999 Feb; 21(1):59-62. PubMed ID: 10068777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phytoestrogen intake from foods, during adolescence and adulthood, and risk of breast cancer by estrogen and progesterone receptor tumor subgroup among Ontario women.
    Anderson LN; Cotterchio M; Boucher BA; Kreiger N
    Int J Cancer; 2013 Apr; 132(7):1683-92. PubMed ID: 22907507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer.
    Magkou C; Giannopoulou I; Theohari I; Fytou A; Rafailidis P; Nomikos A; Papadimitriou C; Nakopoulou L
    Histopathology; 2012 Jun; 60(7):1125-32. PubMed ID: 22320867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
    Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
    Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.
    Doval DC; Sharma A; Sinha R; Kumar K; Dewan AK; Chaturvedi H; Batra U; Talwar V; Gupta SK; Singh S; Bhole V; Mehta A
    Asian Pac J Cancer Prev; 2015; 16(12):4959-64. PubMed ID: 26163622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinico-morphological profile and receptor status in breast cancer patients in a South Indian institution.
    Ghosh S; Sarkar S; Simhareddy S; Kotne S; Rao PB; Turlapati SP
    Asian Pac J Cancer Prev; 2014; 15(18):7839-42. PubMed ID: 25292074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    Fournier A; Fabre A; Mesrine S; Boutron-Ruault MC; Berrino F; Clavel-Chapelon F
    J Clin Oncol; 2008 Mar; 26(8):1260-8. PubMed ID: 18323549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of breast cancer subtypes and body mass index.
    Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
    Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.
    Zubeda S; Kaipa PR; Shaik NA; Mohiuddin MK; Vaidya S; Pavani B; Srinivasulu M; Latha MM; Hasan Q
    Asian Pac J Cancer Prev; 2013; 14(4):2231-5. PubMed ID: 23725118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
    Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
    Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
    Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
    PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.